1. The Reality of Gene Therapy: Hemgenix and Luxturna

In previous articles, we explored the scientific journey that led us from the discovery of the F8 gene (Article 1) to the creation of bio-factories (Article 2) and the use of AAV as a “viral postman” (Article 3). Now, it’s time to talk about the practical results: the gene therapy drugs that have already been approved.

Two notable examples, though for different diseases, illustrate the point well:

  • Hemgenix (for Hemophilia B): Approved in 2022 by the FDA (USA) and in 2023 by the EMA (Europe), Hemgenix is the first single-dose gene therapy for hemophilia B. It uses the AAV vector to deliver a functional copy of the Factor IX gene into the liver, allowing the body to continuously produce this clotting protein 1. Results have been promising, with many patients achieving Factor IX levels sufficient for a life without spontaneous bleeds.
  • Luxturna (for Leber Congenital Amaurosis): Approved in 2017, Luxturna was the first gene therapy approved in the US for a genetic disease. It uses an AAV vector to restore vision in patients with a rare form of inherited vision loss 2.

These drugs are milestones. They transform patients’ lives by treating the root cause of the disease, rather than just managing symptoms. But this innovation comes at an unprecedented cost.

2. The Price of Innovation: Why Millions?

Hemgenix holds the title of the world’s most expensive drug, with a list price of US$ 3.5 million for a single dose. Other gene therapies, such as Zolgensma (for Spinal Muscular Atrophy), also exceed US$ 2 million.

Why these exorbitant prices? It’s a multifaceted issue:

  • Intensive Research and Development (R&D): Decades of research, billions of dollars invested in basic, preclinical, and clinical studies. The failure rate is extremely high; many projects don’t make it to the end.
  • Complex Production: The manufacturing of AAV viral vectors is a highly complex process, requiring specialized facilities (clean rooms), rigorous quality control, and high-tech equipment. It’s not like manufacturing a pill.
  • Single-Dose Treatment: The expectation is that these treatments offer long-lasting benefits, perhaps for a lifetime, replacing years or decades of continuous, expensive therapies. Companies price the total “value” of the long-term cure.
  • Small Market (Rare Diseases): Hemophilia and many other diseases treated by gene therapy are rare. This means that the R&D cost needs to be recouped from a limited number of patients.
  • Patient Value: The value of restoring vision or eliminating the constant risk of bleeding is immeasurable for patients and their families, which also factors into the pricing equation.

3. From List Price to Multi-Million Dollar Patient Cost

It’s important to differentiate the list price from what healthcare systems actually pay. Complex negotiations, discounts, and outcomes-based payment models (where the pharmaceutical company receives installments over time if the treatment continues to work) are common.

However, even with these mechanisms, the impact on healthcare budgets is immense, raising global questions about equity and access to innovation.

4. More Than Cost: Scientific Analysis and Patient Impact

Beyond the financial dilemma, the arrival of these therapies requires continuous scientific analysis:

  • Durability: How long do the effects of gene therapy last? Many Hemgenix patients maintain stable levels for years, but long-term follow-up is crucial.
  • Safety: Although AAV vectors are considered safe, immune reactions and liver inflammation can occur, requiring additional medication (steroids) and monitoring.
  • Functional Cure vs. Total Cure: Currently, these are considered “functional cures,” as the added gene does not alter the patient’s original DNA. The patient still carries the genetic condition but does not exhibit the symptoms.

Science continues to advance, seeking not only more effective and lasting therapies but also more accessible ways to make them available.

➡️ The Continuation of the Series

The cost and complexity of current gene therapy lead us to the next frontier: genetic editing. What if we could correct the error in the code itself?

🔗 References

  1. FDA. (2022). FDA approves first gene therapy for hemophilia B. Accessed on [current date]. ↩︎

  2. FDA. (2017). FDA approves first gene therapy to treat patients with a rare form of inherited vision loss. Accessed on [current date]. ↩︎